AXIL - reviveprocare.com Debt to Book Capitalization Ratio

Graphic logo of AXIL Brands (AXIL)

Cosmetics manufacturer AXIL Brands, Inc. (AXIL) adheres to a clean beauty and recyclable packaging concept, which is supported by this GURU.Markets chart on the share of debt obligations in balance sheet capital; meanwhile, 0.03 shows the current value of this metric. Management is effectively expanding premium accessories via marketplaces, while moderate pricing power allows the company to offset inflation despite aggressive discounting in the mass market.

AXIL (AXIL Brands) Debt to Book Value history from 02/21/2024 to 10/27/2026

reviveprocare.com (AXIL) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price AXIL Brands|AXIL - Analyst Consensus Forecast
- market capitalization data:
Market Value Revive Pro Care|AXIL - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share AXIL Brands|AXIL - Company Net Assets|Market Capitalization to Book Value Ratio reviveprocare.com|AXIL - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio AXIL Brands, Inc.|AXIL - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity AXIL Brands|AXIL - Company Total Debt Obligations|Debt to Book Capitalization Ratio Revive Pro Care
Summary company analytics:Revive Pro Care AXIL
Core merchandise of AXIL Brands

A conservative investor assesses the stability of AXIL Brands, Inc. (AXIL) through the lens of its debt load. For this hearing protection systems manufacturer, the balance of borrowed capital is critical when expanding into B2B and B2C segments. Analyzing this chart of the debt-to-equity structure, we see the ratio of total liabilities to the value of assets minus liabilities. A decrease in this coefficient minimizes default risk, while an increase indicates aggressive scaling of market share. A stable trend confirms the financial reliability of the issuer.

Competitors of AXIL Brands, Inc.

Debts to Book Capitalization KRYS (Krystal Biotech, Inc.)|apogeetherapeutics.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Arcutis Biotherapeutics, Inc. (ARQT)|VCEL: Debt to Net Assets Ratio|ORKA (Oruka Corp) - Debt to Book Capitalization Ratio|Sanara MedTech (SMTI) - Debt to Book Value|DBVT (DBV Tech) - Debts to Book Capitalization|Debts to Book Capitalization Solesence Inc. (SLSN)|Journey Medical (DERM) - Debt to Book Value|Debt to Net Assets Ratio FBRX (Forte Biosciences Inc.)|Debt to Book Capitalization Ratio EMPG|Sol-Gel Technologies, Ltd. - Debts to Net Assets|Medicus Pharma Ltd. - Debt to Book Capitalization Ratio|VRCA - Debts to Book Capitalization|hoththerapeutics.com - Debts to Book Capitalization|BFRI (Biofrontera) - Debts to Net Assets|Debt to Book Capitalization Ratio VYNE Therapeutics, Inc. (VYNE)|Debt to Book Value Ratio Sonoma Pharma|Debts to Book Capitalization QNRX|Debts to Book Capitalization azitrainc.com AZTR|DRMA - Debt to Book Value|Debt to Book Value Ratio Elevai Labs Inc ELAB|Debts to Book Capitalization RVNC (Revance Therapeutics, Inc)